Skip to content

Oral Preoperative Carbohydrate on Early Postoperative Outcome After Cesarean Section

Effects of Oral Preoperative Carbohydrate on Early Postoperative Outcome After Cesarean Section. A Double-Blind Placebo-controlled Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03732404
Enrollment
200
Registered
2018-11-06
Start date
2018-12-01
Completion date
2021-08-01
Last updated
2021-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean Section Complications

Keywords

Enhanced recovery after surgery, Preoperative carbohydrate drink, cesarean section

Brief summary

Preoperative carbohydrate treatments have been widely adopted as part of enhanced recovery after surgery (ERAS) or fast-track surgery protocols. Although fast-track surgery protocols have been widely investigated and have been shown to be associated with improved postoperative outcomes, some individual constituents of these protocols, including preoperative carbohydrate treatment, have not been subject to such robust analysis.

Detailed description

Carbohydrate (sugar-containing) nutritional supplements have become a routine part of the package of care for people undergoing planned surgical procedures. the investigator wanted to discover whether carbohydrate supplements are a useful part of care packages used by doctors to improve recovery after planned cesarean section.

Interventions

Patients in the treatment group will receive a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrin; 240 mOsm/L) in a dose of 800 mL. Patients will be free to drink the beverage from the evening before the operation and up to 2 hours before the induction of anesthesia

DRUGPlacebo

The control group will receive plain water with the same volume and timing of treatment.

Sponsors

Aswan University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

The trial will be appropriately blinded; the participants, outcome assessors and the surgeon performing the procedure will be blinded to the medication type, which was used.

Intervention model description

This is a randomized, placebo-controlled, study.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Pregnant women undergoing elective caesarean section * Term gestational age (37+0 to 41+6 weeks) * Singleton gestation

Exclusion criteria

* Women with gestational diabetes and diabetes mellitus * Fetal intrauterine growth restriction * Ante-natally detected congenital anomaly which will require admission to the neonatal nursery * Women who received steroids within the past 7 days prior to delivery * Women who did not complete a gestational diabetes screening test

Design outcomes

Primary

MeasureTime frameDescription
Length of hospital stay3 weeksNumber of days in the hospital for each participant between the groups.

Secondary

MeasureTime frameDescription
number of participants experienced nausea24 hours postoperativeNumber of participants experienced nausea
Change in preoperative well-being assessment from baseline to one hour using the 100 millimeter (mm) visual analogue scaleist 24 hours postoperative100 mm visual analogue scales for hunger, thirst, anxiety, fatigue and nausea administered on the morning of surgery prior to morning beverage consumption and 60 minutes after the beverage. All measurements will be assessed using the same scale starting at 0 to 100mm with 0 being the worst and 100 being the best and average being 85.
neonatal blood glucose concentration at four and ten hours of age24 hours post operativemeasure neonatal blood glucose level at four and ten hours of age
Neonates with plasma glucose level of less than 45 mg/dL between the groupsist 24 hours postoperativeFirst umbilical cord blood sample will be taken for plasma glucose level of less than 45 mg/dL to note hypoglycemia between the groups.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026